What Is Trulicity?

Trulicity (dulaglutide) is a once-weekly injectable GLP-1 receptor agonist manufactured by Eli Lilly, FDA-approved in September 2014 for type 2 diabetes. Trulicity's unique single-use autoinjector with a hidden needle has made it one of the most widely prescribed GLP-1 medications for patients with injection anxiety. The REWIND trial demonstrated cardiovascular outcome benefits in T2D patients with or at high risk for cardiovascular disease.

Formulation: Weekly subcutaneous injection (single-use autoinjector pen: 0.75, 1.5, 3.0, 4.5 mg)

Mechanism: GLP-1 receptor agonist

Manufacturer: Eli Lilly official patient site ↗

FDA Approved: 2014 — Key Trial: AWARD-11 ↗ (ClinicalTrials.gov)

Who Is Trulicity For?

FDA-Approved Indication: Type 2 diabetes management; cardiovascular risk reduction in T2D with established CVD or high CV risk

Adults with type 2 diabetes mellitus as an adjunct to diet and exercise. Also approved to reduce cardiovascular risk in T2D patients with established CVD or multiple CVD risk factors (REWIND trial). The autoinjector design makes Trulicity particularly suited for patients with injection anxiety or limited dexterity.

Eligibility criteria: BMI criterion not required; indicated for T2D management

Dosing & Titration Schedule

The standard titration protocol for Trulicity (Dulaglutide) allows your body to adjust gradually to the medication, minimizing GI side effects. Each dose is typically maintained for 4 weeks before escalation, though your prescriber may modify this based on tolerability.

Dose	Approx. Weeks	Frequency	Phase
0.75 mg	Wk 1–4	Weekly	▶ Starting dose
1.5 mg	Wk 5–8	Weekly	→ Escalation
3.0 mg	Wk 9–12	Weekly	→ Escalation
4.5 mg	Wk 13–16	Weekly	★ Maintenance

Data source: FDA Prescribing Information for Trulicity. Individual titration may vary based on tolerability and clinical response.

Weight Loss & Glycemic Outcomes

Clinical trial evidence (AWARD-11): ~4.5% body weight at 4.5 mg (AWARD-11, 36 weeks)

Cardiovascular benefit: Trulicity has demonstrated cardiovascular outcome benefits in clinical trials. Discuss cardiovascular risk reduction with your prescriber.

These figures are based on clinical trial populations meeting specific inclusion criteria. Real-world results may differ due to adherence, diet, activity level, and individual biology. Calculate your projected weight loss →

Side Effect Profile

The most commonly reported side effects of Trulicity are GI-related, typically most pronounced during dose escalation. They generally improve within 2–4 weeks at a stable dose.

•Nausea
•Diarrhea
•Abdominal Pain
•Vomiting
•Fatigue
•Injection Site Reaction
•Headache

For detailed guidance on managing specific side effects, see the Dulaglutide side effects hub →

Cost Overview

Scenario	Estimated Monthly Cost
Cash pay (no insurance)	$700–$800/month
Commercial insurance	$25–$50/month with commercial insurance and Eli Lilly savings card
Manufacturer savings program	Eli Lilly Trulicity Savings Card — eligible commercially insured patients may significantly reduce costs

Estimated based on Q1 2026 data. Prices vary by pharmacy, region, and insurance plan. Always verify current pricing with your pharmacy or plan.

Visit Eli Lilly’s savings program ↗ | Estimate your monthly cost →

Safety & Contraindications

Trulicity carries a Boxed Warning regarding the risk of thyroid C-cell tumors (based on animal studies). The clinical relevance in humans is unknown, but the following contraindications apply:

Personal or family history of medullary thyroid carcinoma
MEN type 2 syndrome
Hypersensitivity to dulaglutide
Severe gastrointestinal disease

Pregnancy: Trulicity is not recommended during pregnancy. Discontinue at least 2 months before a planned pregnancy when possible. Discuss contraception and family planning with your prescriber.

Drug interactions: Delayed gastric emptying; hypoglycemia risk with insulin/sulfonylureas.

How Does Trulicity Compare to Other Options?

See all brand comparisons →

Frequently Asked Questions

Why do people prefer Trulicity's injector?

Trulicity uses a single-use autoinjector with a retractable needle that users never see. The needle automatically retracts after injection. This design is favored by patients with needle phobia or those managing T2D for the first time.

How much weight loss does Trulicity cause?

Weight loss is a secondary benefit. In AWARD-11, Trulicity at 4.5 mg produced ~4.5% mean body weight reduction. This is modest compared to semaglutide or tirzepatide, reflecting dulaglutide's primary focus on glycemic control.

What is the REWIND trial?

REWIND (N=9,901, median 5.4 years) demonstrated that Trulicity reduced major adverse cardiovascular events by 12% in T2D patients with or at high risk for CVD — including patients without prior cardiovascular disease, a broader population than some competing trials.

What is the Trulicity titration schedule?

Start at 0.75 mg weekly for at least 4 weeks → 1.5 mg (standard maintenance) → 3.0 mg (if additional control needed) → 4.5 mg (maximum). Most T2D patients achieve goals at 1.5 mg.

Is Trulicity good for weight loss?

Trulicity produces modest weight loss (~2–4.5%) as a secondary effect. For weight loss as a primary goal, medications specifically approved for obesity (Wegovy, Zepbound, Saxenda) produce substantially greater weight reduction.

How does Trulicity compare to Ozempic?

Both are weekly GLP-1 receptor agonists for T2D. Semaglutide (Ozempic) generally produces greater HbA1c reduction and weight loss in clinical comparisons. However, Trulicity's injection device is preferred by some patients, and it has a longer post-market safety record.

Can I take Trulicity if I have kidney disease?

Trulicity can be used across a range of kidney function levels without dose adjustment. Unlike some older diabetes medications, no specific renal dose adjustments are required, though as with any medication, monitoring is recommended in severe renal impairment.

Trulicity: Complete Guide to Dulaglutide (2026)